http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Keon Woo Park,Young-Hyuc kIm,이지연,Eungho Kim,Hyuk Lee,Bong Geun Song,Joon Oh Park,Kihyun Kim,정철원,Young Suk Park,Won Ki Kang,Mark H. Lee,Keunchil Park 대한암학회 2003 Cancer Research and Treatment Vol.35 No.5
uncommon and typically occurs in patients with disseminated diseases. This may cause difficulty in differentiating it from primary gastric carcinoma. The correct diagnosis of the primary source is important, since the treatment and prognosis of metastatic breast cancer is quite different from those of metastatic gastric cancer. Immunohistochemical staining with GCDFP-15 (gross cystic disease fluid protein-15) can be used to differentiate primary gastric carcinoma and gastric metastasis from breast cancer. We report two cases of gastric metastasis of breast cancer by describing their clinical course, illustrating the histologic findings, and showing the results of immunohistochemical staining with GCDFP-15. (Cancer Res Treat. 2003;35:460-464)
Park, Soo Bin,Choi, Joon Young,Moon, Seung Hwan,Yoo, Jang,Kim, Hojoong,Ahn, Yong Chan,Ahn, Myung-Ju,Park, Keunchil,Kim, Byung-Tae BioMed Central 2014 Cancer imaging Vol.14 No.1
<P><B>Background</B></P><P>We evaluated the prognostic value of volume-based metabolic positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC) compared with other factors.</P><P><B>Methods</B></P><P>The subjects were 202 patients with pathologically proven SCLC who underwent pretreatment <SUP>18</SUP>F-fluorodeoxyglucose (FDG) PET/computed tomography (CT). Volumetric metabolic parameters of intrathoracic malignant hypermetabolic lesions, including maximum and average standardized uptake value, sum of metabolic tumor volume (MTV), and sum of total lesion glycolysis (TLG) were measured.</P><P><B>Results</B></P><P>164 patients had died during follow-up (median 17.4 months) and median overall survival was 14 months. On univariate survival analysis, age, stage, treatment modality, sum of MTV (cutoff = 100 cm<SUP>3</SUP>), and sum of TLG (cutoff = 555) were significant predictors of survival. There was a very high correlation between the sum of MTV and the sum of TLG (r = 0.963, <I>P</I> < 0.001). On multivariate survival analysis, age (HR = 1.04, <I>P</I> < 0.001), stage (HR = 2.442, <I>P</I> < 0.001), and sum of MTV (HR = 1.662, <I>P</I> = 0.002) were independent prognostic factors. On subgroup analysis based on limited disease (LD) and extensive disease (ED), sum of MTV and sum of TLG were significant prognostic factors only in LD.</P><P><B>Conclusion</B></P><P>Both sum of MTV and sum of TLG of intrathoracic malignant hypermetabolic lesions are important independent prognostic factors for survival in patients with SCLC, in addition to age and clinical stage. However, it may be more useful in limited disease rather than in extensive disease.</P>
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park, Sanghui,Choi, Yoon-La,Sung, Chang Ok,An, Jungsuk,Seo, Jinwon,Ahn, Myung-Ju,Ahn, Jin Seok,Park, Keunchil,Shin, Young Kee,Erkin, Ozgur Cem,Song, Kyung,Kim, Jhingook,Shim, Young Mog,Han, Joungho Gutenberg 2012 Histology and histopathology Vol.27 No.2
<P>The aim of this study was to evaluate the prevalence and prognostic role of increased gene copy number and protein expression of MET and EGFR in non-small cell lung cancer (NSCLC) patients. Samples were collected from 380 patients with surgically resected NSCLC, and fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) were performed. EGFR amplification and high polysomy (EGFR FISH-positive) were observed in 9.7% and 17.4% of the patients, respectively. EGFR was overexpressed (EGFR IHC-positive) in 19.2% of the patients. Neither EGFR FISH-positive nor EGFR IHC-positive status affected survival after resection. Increased MET copy number (MET FISH-positive by University of Colorado Cancer Center criteria) was observed in 11.1% of the patients (high polysomy, 8.7%; gene amplification, 2.4%). According to the Cappuzzo system, 7.1% of the patients were MET FISH-positive. MET FISH positivity was a negative prognostic factor, especially in patients with adenocarcinoma histology (p=0.040), female gender (p=0.010), old age (p=0.084), and EGFR FISH negativity (p=0.020) at the univariate level but not at the multivariate level. MET was overexpressed (MET IHC-positive) in 13.7% of the patients and associated with shorter overall and disease-free survival (p=0.010 and p=0.056, respectively). Multivariate analysis revealed that MET IHC-positive patients had a significantly increased risk of death (hazard ratio, 1.618; 95% confidence interval, 1.066-2.456; p=0.024). Increased MET copy number and MET overexpression are negative prognostic factors for surgically resected NSCLCs.</P>
박원(Won Park),안용찬(Yong Chan Ahn),임도훈(Do Hoon Lim),백정환(Chung Whan Baek),손영익(Young Ik Son),박근칠(Keunchil Park),김경주(Kyoung Ju Kim),이정은(Jeong Eun Lee),강민규(Min Kyu Kang),박영제(Young Je Park),남희림(Hee Rim Nam),허 대한방사선종양학회 2003 Radiation Oncology Journal Vol.21 No.4
목 적: 편도암으로 진단받고 근치적 목적의 치료를 시행받은 환자들의 치료성적을 후향적으로 분석하여 그 결과를 보고하고자 하였다. 대상 및 방법 : 1995년 1월부터 2000년 12월까지 삼성서울병원에서 편도의 편평상피세포암으로 진단받고 근치적 목적의 치료가 시행된 27례를 대상으로 하였다.대상환자들에 대한 국소 치료법의 결정은 두경부 종양 협진팀에서 합의하여 결정하였으며, 방사선치료를 우선적으로 고려하였던 기준은 (1) 환자측 요인으로 전신마취와 수술의 위험이 큰 경우, (2) 환자의 수술 거부, (3) 근치적 수술 절제가 여의치 않거나, (4) 수술 후 기능장애가 클 것으로 예견된 경우 등이었다. 국소치료법으로 수술을 우선적으로 시행하고 수술 후 방사선치료를 선별적으로 추가한 경우가 17명이었고(S±RT군), 근치적 방사선치료 단독 혹은 동시병용 방사선-항암화학요법을 시행한 경우가 10명이었다(RT±CT군). 대상 환자들에 대한 추적관찰기간은 3˜ 94 (중앙값 41)개월이었다. 결 과:AJCC 병기는 I˜ II병기가 4명, III병기가 2명, IV병기가 21명이었다. 전체 환자의 5년 무병생존율은 73.3% 였고, S±RT군과 RT±CT군 각각 70.6%와 77.8%였다. 관찰기간 중 모두 7명에서 재발이 발현 하였으며,이들은 모두 III˜IV병기 환자들이었고 치료개시 후 2년 이내에 재발하였다. S±RT군에서는 국소재발 2명 , 영역재발 2명, 원격전이 1명을 포 함 하 여 모두 5명이 재발하였고(조재발률=29.4%),RT±CT군 에서는 국소+영역재발 1명,원격전이 1명을 포함하여 2명이 재발하였다(조 재발률=20%).전체 환자의 5년 생존율은 77.0%였고, S±RT군과 RT±CT군별로는 각각 80.9%와 70.0%였다. 결 론: 저자들은 편도암에 대한 국소치료법으로서 수술을 주로 적용한 경우와 방사선치료를 주로 적용한 경우 모두에서 다른 문헌들에서 보고되는 국소제어율,생존율과 비슷한 수준의 비교적 좋은 치료결과를 얻을 수 있었다. 국소적으로 진행된 편도암에서 방사선치료를 근간으로 하는 치료법은 수술에 의한 기능장애를 피할 수 있는 대안으로 판단된다. Purpose: To report the results of curative treatment for patients with tonsil cancer by retrospective analysis. Materials and Methods: From Jan. 1995 till Dec. 2000, 27 patients with squamous cell carcinoma of the tonsil received curative treatment at Samsung Medical Center. Therapeutic decision was made throughmultidisciplinary conference, and curative radiation therapy was favored when, (1) the patient's condition was not fit for general anesthesia and surgery, (2) the patient refused surgery, (3) complete resection was presumed impossible, or (4) too severedisability was expected after surgery. Surgery was the main local modality in 17 patients (S± RT group), and radiation therapy in 10 (RT± CT group). T he median follow-up period was 41 months. Results: AJCC stages were I/II in four, III in two, and Iv in 21 patients. The 5-year disease-free survival rate was 73.3% in all patients, 70.6% in the S ± RT group, and 77.8% in the RT ± CT group. Treatment failure occurred in seven patients, all with stage III/IV, and all the failures occurred within 24 months of the start of treatment. Five patients among the S ± CT group developed treatment failures; 2 local, 2 regional, and 1 distant (crude rate=29.4%). Two patients a m o ng the RT± CT group developed failures; 1 synchronous local and regional, and 1 distant (crude rate=20.0%). The 5-year overall survival rate was 77.0% in all patients, 80.9% in the S ± RT group, and 70.0% in the R T ± CT group. Conclusion: We could achieve favorable results that were comparable to previously reported data with respect to both the rates of local control and of survival by applying S± RT and RT± C T . RT± C T is judged to be an alternative option that can avoid the functional disability after surgical resection.
The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation
Lee Se Hoon,Park Joon Oh,Jung Chul Won,Park Keunchil,Lee Kyoo Hyung,Lee Mark Hong,Lee Kyung Eun,Park Jinny,Kim Kihyun,Kim Won Seog,Im Young Hyuk,Kang Won Ki,Kim Seon Woo,Lee Je Hwan,Park Se Hoon 대한의학회 2004 Journal of Korean medical science Vol.19 No.1
최용성,정철원,김정,박건우,서연림,박세훈,박근칠 대한내과학회 2004 대한내과학회지 Vol.66 No.6
저자 등은 하복부 통증으로 내원한 45세 여자 환자를 통해 난소의 낭성 기형종에서 발생한 원발성 악성 흑생종을 경험하였고, 추척 중에 발생한 이 환자의 다발성 전이를 수술 및 면역 화학 요법을 시행하여 치료 중인 증례를 이에 대한 문헌 고찰과 더불어 보고를 하는 바이다. Primary malignant melamona arising in a cystic teratoma of ovary is extremely rare. Approximately 25 cases of primary malignant melanoma arising from a cystic teratoma in ovary have been reported in the literature. The malignant transformation of benign cystic teratoma of ovary usually develops unilaterally in postmenopausal women. The common presenting symptoms are abdominal distention, lower abdominal pain and a palpable abdominal mass. We report a case of primary malignant melanoma of ovary in a 45 year-old patient who underwent laparotomy for evaluation of a cystic mass in right ovarian cystic teratoma. Histopathological examination of the cyst showed that it was melanoma with pre existed teratomatous components. Extraovarian primary site was not found. Nine years after the excision, brain metastases developed which were pathologically confirmed as metastatic melanoma. The patient subsequently developed pulmonary metastases and received immunochemotherappy consisting of cisplatin, dacarbazine, vinblastine, interleukin 2 and interferone α. She is on a regular follow-up and continues to have stable disease for 9 months.
Three Cases of Synchronous Solid Tumor and Multiple Myeloma
Sang Hoon Ji,이지연,Mi Jung Oh,Keun Woo Park,Kihyun Kim,정철원,Young-Hyuck Im,Keunchil Park,oon Oh Park,임도형,Se-Hoon Lee,Young Suk Park,Mark H Lee,박병배,Won Seog Kim,Won Ki Kang 대한암학회 2004 Cancer Research and Treatment Vol.36 No.5
The association between a multiple myeloma and a secondary solid tumor is not well established. Some reports showed an increased risk of secondary solid neoplasms in multiple myeloma patients, but others have not. Three cases of the synchronous occurrence of multiple myelomas and solid tumors, namely, a small cell carcinoma of the lung, an adenocarcinoma of the colon and a squamous carcinoma of the pyriform sinus were experienced at our hospital. Therefore, herein is reported the clinical courses and treatment results. The stage of multiple myeloma was Durie-Salmon stage I in all of three cases; therefore, the solid tumors were treated as a primary target because the prognosis of early stage multiple myeloma is generally better than that of advanced solid tumor, while a smoldering or stage I myeloma do not need primary therapy until progression of the multiple myeloma. Two patients died of their solid tumors, but one patient is alive. (Cancer Res Treat. 2004;36:338-340)
Esophageal Squamous Cell Carcinoma Recurring as a Solitary Renal Mass
임도형,Sang Hoon Ji,박병배,이지연,Keun Woo Park,Joon-Oh Park,Kihyun Kim,정철원,Young Suk Park,Won Ki Kang,Kwanmien Kim,Young Mog Shim,Young-Hyuck Im,Mi Jung Oh,Se-Hoon Lee,Won Seog Kim,Mark H Lee,Keunchil Park 대한암학회 2004 Cancer Research and Treatment Vol.36 No.4
Herein, a case of solitary, unilateral renal metastasis in a patient with curatively resected thoracic esophageal carcinoma, who achieved a pathological complete remission after neoadjuvant concurrent chemoradiotherapy, is reported. The kidney is the 4th or 5th most common visceral metastasis site of a primary esophageal carcinoma. More than 50& of renal metastases typically show bilateral involvement. Solitary, unilateral renal metastasis is extremely rare. Renal metastases from a primary esophageal carcinoma are usually latent and its diagnosis is very unusual in a live patient. The solitary renal metastasis in this case was not accompanied by metastases to other sites. The value of a nephrectomy in solitary renal metastasis of esophageal cancer is not known due to the rarity of such cases. A nephrectomy could be justified in limited situations, such as with uncertainty of histological diagnosis, severe life-threatening hematuria, which cannot be controlled by embolization, or solitary renal metastasis with a long disease-free interval.(Cancer Res Treat. 2004;36:271-274)